INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Other Events

ME Staff 8-k
-
0

INNOVIVA,INC. (NASDAQ:INVA) Files An 8-K Other Events
Item 9.01. Other Events.

On January26, 2018, GlaxoSmithKline plc (GSK) and Innoviva,Inc. (Innoviva) issued a press release announcing that the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive opinion recommending a label update for the use of once-daily RELVAR® ELLIPTA® (fluticasone furoate/vilanterol, FF/VI), an inhaled corticosteroid (ICS) / long-acting beta2 agonist (LABA) combination, in patients whose asthma is already adequately controlled on both an inhaled corticosteroid and long-action beta2 agonist.

RELVAR® ELLIPTA® has been developed under the LABA collaboration agreement between GSK and Innoviva.

The press release is filed as Exhibit99.1 to this report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

99.1

Press Release dated January26, 2018


Innoviva, Inc. Exhibit
EX-99.1 2 a18-3840_1ex99d1.htm EX-99.1 Exhibit 99.1   PRESS RELEASE   Issued: 26 January 2018 London UK and Brisbane,…
To view the full exhibit click here

About INNOVIVA,INC. (NASDAQ:INVA)

Innoviva, Inc., formerly Theravance, Inc., focuses on bringing new medicines to patients in areas of unmet need. The Company is engaged in the development, commercialization and financial management of bio-pharmaceuticals. Its portfolio focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol (FF/VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). It operates in providing capital return to stockholders by maximizing the potential value of its respiratory assets partnered with GSK segment. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of VI, a LABA and FF, an inhaled corticosteroid (FF/VI) delivered via the ELLIPTA dry powder inhaler. ANORO ELLIPTA is a dual bronchodilator consisting of UMEC, a long-acting muscarinic antagonist (LAMA) and VI, a LABA for the treatment of chronic obstructive pulmonary diseases (COPD).